SIGA Technologies, Inc. (SIGA)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Diem Nguyen M.B.A., Ph.D.
|
CEO & Director | 1.39M | -- | 1972 |
|
Mr. Daniel J. Luckshire CPA, M.B.A.
|
Executive VP, CFO & Secretary | 1.32M | -- | 1971 |
|
Dr. Dennis E. Hruby Ph.D.
|
Executive VP & Chief Scientific Officer | 1.31M | -- | 1952 |
|
Mr. Lawrence R. Miller Esq., J.D.
|
General Counsel & Corporate Secretary | 1.04M | -- | 1968 |
|
Mr. Herb Vloedman
|
Senior VP & Chief Information Officer | -- | -- | -- |
|
Suzanne Harnett
|
Senior Vice President of Corporate Affairs & Investor Relations | -- | -- | -- |
SIGA Technologies, Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 49
Description
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.
Corporate Governance
Upcoming Events
November 9, 2026 at 9:00 PM UTC
SIGA Technologies, Inc. Earnings Date
Recent Events
April 23, 2026 at 12:00 AM UTC
Dividend Date
April 7, 2026 at 12:00 AM UTC
Ex-Dividend Date
